Literature DB >> 19451661

Understanding and treating alcohol craving and dependence: recent pharmacological and neuroendocrinological findings.

Lorenzo Leggio1.   

Abstract

There is a substantial need for discovering innovative ways to provide more information on the neurobiology of alcohol dependence as well as to discover more effective pharmacotherapies for alcohol dependence. Current research includes exploring new pathways able to modulate alcohol craving. In particular, research shows that several neuroendocrinological pathways may be involved in the neurobiology of alcohol craving and dependence. The first part of this review examines recent clinical findings on the role of feeding-related peptides in alcohol craving and dependence. Second, this review focuses on the need to discover new medications that may prove to be safe and effective in the treatment of alcohol dependence. For example, the GABA(B) receptor has been suggested as a new possible neuropharmacological target in the treatment of alcohol dependence. Accordingly, the second part of this review examines recent clinical findings on the role of the selective GABA(B) receptor agonist baclofen in the treatment of alcohol-dependent subjects. These two distinct topics will be both analyzed and discussed. The final part of this review discusses possible connections between these two topics, as an example of possible interactions between psychoneuroendocrinology and neuropharmacology. These possible interactions could lead to future intriguing research aimed at understanding and treating alcohol craving and dependence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19451661     DOI: 10.1093/alcalc/agp026

Source DB:  PubMed          Journal:  Alcohol Alcohol        ISSN: 0735-0414            Impact factor:   2.826


  7 in total

Review 1.  The relationship of appetitive, reproductive and posterior pituitary hormones to alcoholism and craving in humans.

Authors:  George A Kenna; Robert M Swift; Thomas Hillemacher; Lorenzo Leggio
Journal:  Neuropsychol Rev       Date:  2012-07-07       Impact factor: 7.444

2.  Investigating dimensionality and measurement bias of DSM-5 alcohol use disorder in a representative sample of the largest metropolitan area in South America.

Authors:  João Mauricio Castaldelli-Maia; Yuan-Pang Wang; Guilherme Borges; Camila M Silveira; Erica R Siu; Maria C Viana; Arthur G Andrade; Silvia S Martins; Laura H Andrade
Journal:  Drug Alcohol Depend       Date:  2015-05-09       Impact factor: 4.492

3.  Effects of alcohol availability, access to alcohol, and naltrexone on self-reported craving and patterns of drinking in response to an alcohol-cue availability procedure.

Authors:  Marc I Kruse; Alexander J Radnovich; Raj K Kalapatapu; Nicole Mehdiyoun; R Andrew Chambers; Dena Davidson
Journal:  J Stud Alcohol Drugs       Date:  2012-03       Impact factor: 2.582

4.  Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.

Authors:  Lorenzo Leggio; Anna Ferrulli; Silvia Cardone; Antonio Nesci; Antonio Miceli; Noemi Malandrino; Esmeralda Capristo; Benedetta Canestrelli; Palmiero Monteleone; George A Kenna; Robert M Swift; Giovanni Addolorato
Journal:  Addict Biol       Date:  2011-03-11       Impact factor: 4.280

5.  Intravenous ghrelin administration increases alcohol craving in alcohol-dependent heavy drinkers: a preliminary investigation.

Authors:  Lorenzo Leggio; William H Zywiak; Samuel R Fricchione; Steven M Edwards; Suzanne M de la Monte; Robert M Swift; George A Kenna
Journal:  Biol Psychiatry       Date:  2014-03-25       Impact factor: 13.382

6.  Leptin levels are reduced by intravenous ghrelin administration and correlated with cue-induced alcohol craving.

Authors:  C L Haass-Koffler; E G Aoun; R M Swift; S M de la Monte; G A Kenna; L Leggio
Journal:  Transl Psychiatry       Date:  2015-09-29       Impact factor: 6.222

7.  The Neural Processes Interlinking Social Isolation, Social Support, and Problem Alcohol Use.

Authors:  Thang M Le; Wuyi Wang; Simon Zhornitsky; Isha Dhingra; Yu Chen; Sheng Zhang; Chiang-Shan R Li
Journal:  Int J Neuropsychopharmacol       Date:  2021-04-21       Impact factor: 5.176

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.